Barrier to Resistance of Dolutegravir in Two-Drug Combinations

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2019 Jan 4

PMID 30602514

Citations 7

Authors

Tomokazu Yoshinaga

Shigeru Miki

Shinobu Kawauchi-Miki

Takahiro Seki

Tamio Fujiwara

Affiliations

Soon will be listed here.

Abstract

A major concern when using two-drug anti-HIV regimens is the risk of viral resistance. However, no techniques to evaluate the barrier to resistance of two-drug combinations have been reported. We evaluated the emergence of drug-resistant mutants in a passage study with constant concentrations of two drugs simultaneously. The barrier to resistance of dolutegravir-containing two-drug combinations was higher than the other combinations evaluated in this study.

Citing Articles

Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine.

Nagarajan P, Zhou J, Di Teodoro G, Incardona F, Seguin-Devaux C, Kaiser R Viruses. 2024; 16(11).

PMID: 39599830 PMC: 11599002. DOI: 10.3390/v16111715.

Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments.

Tao K, Zhou J, Nagarajan P, Tzou P, Shafer R Antiviral Res. 2024; 230:105988.

PMID: 39154752 PMC: 11412686. DOI: 10.1016/j.antiviral.2024.105988.

Combating antimicrobial resistance in malaria, HIV and tuberculosis.

Duffey M, Shafer R, Timm J, Burrows J, Fotouhi N, Cockett M Nat Rev Drug Discov. 2024; 23(6):461-479.

PMID: 38750260 DOI: 10.1038/s41573-024-00933-4.

Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?.

Harper J, Betts M, Lichterfeld M, Muller-Trutwin M, Margolis D, Bar K Pathog Immun. 2024; 8(2):115-157.

PMID: 38455668 PMC: 10919397. DOI: 10.20411/pai.v8i2.665.

Modern antiretroviral regimens in pregnant women: virologic outcomes and durability.

Smith C, Silveira L, Crotteau M, Garth K, Canniff J, Fetters K AIDS. 2023; 38(1):21-29.

PMID: 37289582 PMC: 11375792. DOI: 10.1097/QAD.0000000000003616.

References

Wainberg M, Salomon H, Gu Z, Montaner J, Cooley T, McCaffrey R . Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS. 1995; 9(4):351-7. View

Selleseth D, Talarico C, Miller T, Lutz M, Biron K, Harvey R . Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob Agents Chemother. 2003; 47(4):1468-71. PMC: 152503. DOI: 10.1128/AAC.47.4.1468-1471.2003. View

Cahn P, Sierra Madero J, Arribas J, Antinori A, Ortiz R, Clarke A . Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised,.... Lancet. 2018; 393(10167):143-155. DOI: 10.1016/S0140-6736(18)32462-0. View

Nakahara K, Wakasa-Morimoto C, Kobayashi M, Miki S, Noshi T, Seki T . Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res. 2008; 81(2):141-6. DOI: 10.1016/j.antiviral.2008.10.007. View

Quashie P, Oliviera M, Veres T, Osman N, Han Y, Hassounah S . Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J Virol. 2015; 89(6):3163-75. PMC: 4337543. DOI: 10.1128/JVI.03353-14. View

Adachi A, Gendelman H, Koenig S, Folks T, Willey R, Rabson A . Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986; 59(2):284-91. PMC: 253077. DOI: 10.1128/JVI.59.2.284-291.1986. View

Soriano V, Fernandez-Montero J, Benitez-Gutierrez L, de Mendoza C, Arias A, Barreiro P . Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf. 2017; 16(8):923-932. DOI: 10.1080/14740338.2017.1343300. View

Johns B, Kawasuji T, Weatherhead J, Taishi T, Temelkoff D, Yoshida H . Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med Chem. 2013; 56(14):5901-16. DOI: 10.1021/jm400645w. View

Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K . Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2007; 82(2):764-74. PMC: 2224569. DOI: 10.1128/JVI.01534-07. View

10.

Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown K, Ferris R . In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2010; 55(2):813-21. PMC: 3028777. DOI: 10.1128/AAC.01209-10. View

11.

van Lunzen J, Pozniak A, Gatell J, Antinori A, Klauck I, Serrano O . Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study. J Acquir Immune Defic Syndr. 2015; 71(5):538-43. PMC: 4804741. DOI: 10.1097/QAI.0000000000000904. View

12.

Harada S, Koyanagi Y, Yamamoto N . Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science. 1985; 229(4713):563-6. DOI: 10.1126/science.2992081. View

13.

Lambert-Niclot S, George E, Pozniak A, White E, Schwimmer C, Jessen H . Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. J Antimicrob Chemother. 2015; 71(4):1056-62. DOI: 10.1093/jac/dkv427. View

14.

Aquaro S, Perno C, Balestra E, Balzarini J, Cenci A, Francesconi M . Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol. 1997; 62(1):138-43. DOI: 10.1002/jlb.62.1.138. View

15.

Pham H, Mesplede T, Wainberg M . Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses. Retrovirology. 2016; 13(1):31. PMC: 4851780. DOI: 10.1186/s12977-016-0265-x. View

16.

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

17.

Oliveira M, Ibanescu R, Pham H, Brenner B, Mesplede T, Wainberg M . The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir. AIDS. 2016; 30(15):2267-73. DOI: 10.1097/QAD.0000000000001191. View

18.

Tisdale M, Kemp S, Parry N, Larder B . Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993; 90(12):5653-6. PMC: 46779. DOI: 10.1073/pnas.90.12.5653. View

19.

Singhroy D, Wainberg M, Mesplede T . Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. Antimicrob Agents Chemother. 2015; 59(5):2882-5. PMC: 4394770. DOI: 10.1128/AAC.05181-14. View

20.

Azijn H, Tirry I, Vingerhoets J, de Bethune M, Kraus G, Boven K . TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2009; 54(2):718-27. PMC: 2812151. DOI: 10.1128/AAC.00986-09. View